Early Onset of Minimal change Nephrotic Syndrome during Treatment with D-penicillamine in a Patient with Wilson s Disease.
- Author:
Ki Soo KIM
1
;
Eun Jung CHEON
;
Jae Woo LIM
;
Kyong Og KO
;
Yoon Mee KIM
Author Information
1. Departments of Pediatrics, College of Medicine, Konyang University, Taejon, Korea. kcm1000@kyuh.co.kr
- Publication Type:Case Report
- Keywords:
Wilson`s disease;
D-penicillamine;
Nephrotic syndrome
- MeSH:
Brain;
Child, Preschool;
Cornea;
Female;
Glomerulonephritis, Membranous;
Humans;
Liver;
Nephrosis, Lipoid*;
Nephrotic Syndrome;
Penicillamine*;
Trientine;
Zinc Sulfate
- From:Journal of the Korean Society of Pediatric Nephrology
2004;8(2):250-255
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Wilson s disease is an autosomal recessive disorder characterized by degenerative changes in the brain, liver, and cornea. Treatment includes D-penicillamine, trientine, and zinc sulfate. D-penicillamine has been used frequently as first line therapy for Wilson s disease. However, nephrotoxicity can occur after D-penicillamine treatment. Among them membranous glomerulopathy is the most common histological abnormality but minimal change lesions have also been reported. Nephrotic syndrome is a late complication of D-penicillamine treatment but very rarely can occur within 2 months after treatment of D-penicillamine. We report the early development of minimal change nephrotic syndrome in a 3-year-old girl with Wilson s disease 3 weeks after initiation of D-penicillamine.
